Title: LegoChem plans to turn a prot through licensing-out next year

Publication: Segye Finance

Date: 24 April 2013

Summary

• In press conference held in Yeoui-Do on18th, CEO Kim announced that he will demonstrate improved results through joint research and license-out with pharmaceutical companies, including AstraZeneca, Sanofi Aventis and Green Cross.

• Since early 1990s, only around 50 license-outs have taken place in Korea. Most of them were achieved by large pharmas including LG Life Science, Hanmi Pharmaceuticals, and DongA Pharmaceuticals. However, with experienced and skilled professionals, LegoChem was able to make 7 licensing-out deals since inception. 

• CEO Kim said “among the 7 license-out contracts, one with the AstraZeneca was worth 1.4 billion dollars, historically the largest amount for a candidate substance.

• LegoChem became an IPO of KOSDAQ market through New Growth Engine Company special evaluation and is now anticipating up to $20m (KRW 20bn) funding from public offering.

To view the full article (in Korean), click here ▶

About LegoChem Biosciences

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).